Ng, Khai P <br/><br/>
Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): study protocol for a randomized controlled pilot trial.  [electronic resource] 

 -  Trials  May 2014 
 - 158 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1745-6215 
<br/><br/><label>Standard No.: </label>10.1186/1745-6215-15-158  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Attitude of Health Personnel<br/>Biomarkers--blood<br/>Cardiovascular Diseases--diagnosis<br/>Clinical Protocols<br/>Double-Blind Method<br/>Early Diagnosis<br/>England<br/>General Practitioners--psychology<br/>Health Knowledge, Attitudes, Practice<br/>Humans<br/>Hyperkalemia--blood<br/>Kidney Failure, Chronic--complications<br/>Mineralocorticoid Receptor Antagonists--adverse effects<br/>Pilot Projects<br/>Potassium--blood<br/>Predictive Value of Tests<br/>Primary Health Care<br/>Prospective Studies<br/>Pulse Wave Analysis<br/>Qualitative Research<br/>Research Design<br/>Spironolactone--adverse effects<br/>Surveys and Questionnaires<br/>Time Factors<br/>Treatment Outcome<br/>Vascular Stiffness--drug effects